The contentious role of intellectual property in cryptographic standardisation

No items found.
​
January 12, 2026

A good cryptologist, in similarity to a good patent attorney, is paranoid. One of the largest bouts of paranoia that has (probably rightfully) infected the field of cryptology is the threat posed by a quantum computer on public-key encryption. Using Shor’s algorithm, a quantum computer may break the ubiquitous public-key cryptosystems based on the order finding problem, such as RSA and elliptic-curve cryptography. Consequently, a substantial amount of cryptographic research has thus been directed towards developing quantum-safe alternatives for public-key cryptography, in a field known as Post-Quantum Cryptography (PQC). In 2024, the National Institute of Standards and Technology (NIST) published the first PQC standards, affectionately dubbed FIPS 203, 204 and 205. This article examines the selection process from an intellectual property perspective and highlights some uncommon, though not unprecedented, features of the path to cryptographic standardisation.

The usual selection process involves multiple rounds of public evaluation. In the case of PQC, NIST called for submissions in 2016, admitted 69 complete candidates into the first round, which were narrowed down to finalists and alternates in subsequent rounds, and issued the first standards in 2024. Typically, researchers submit cryptosystems, often accompanied by intellectual property statements. The community evaluates security, performance, and implement ability, and NIST publishes rationales and drafts for public comment before finalisation. Researchers prioritise the dissemination of standards and secure communications and therefore usually permit free use of potentially patentable subject matter (such as implementations of protocols). However, history provides notable exceptions, which we will explore below.

Historical examples: RSA and ECC

The encumbrance of patents does not automatically disqualify a specific cryptosystem from standardisation, but standard setting organisations and government agencies now typically require either royalty free or FRAND (fair, reasonable, and non discriminatory) licenses, or at minimum explicit disclosures, to avoid later disputes. The case of RSA is illustrative as a historic example as to why. The US patent 4 405 829 was granted in 1983 to MIT disclosing the encryption scheme, with a filing date in 1977 ​[1]​. An academic publication by the inventors had been published in 1976, which sparked many implementations of the RSA cryptosystem into software. After the patent was granted, the company RSA Security together with MIT started enforcing it, which likely stifled wide adoption of the cryptosystem but made RSA a commercial success. The patent was set to expire in September 2000 but was surprisingly released two weeks early into the public domain as a “symbolic next step in the evolution of this market” ​[2]​, perhaps to garner goodwill in the community.

The standardisation of elliptic-curve cryptography (ECC) has long been an area of uncertainty regarding intellectual property. ECC was never widely adopted despite offering advantages such as smaller key sizes in comparison to RSA. According to cryptologist Daniel J. Bernstein, “popular rumour states that elliptic-curve cryptography is a patent minefield” ​[3]​. This perception likely arose from patents covering efficient implementation techniques for ECC, although alternative implementations existed that were not patented ​[4]​. This contrasts with RSA, where the cryptosystem itself was patented. Although the NSA sought to license the relevant implementation details for standardisation, and elliptic-curve Diffie-Hellman was later incorporated into NIST standard SP 800-56Ar3, ECC never achieved broad adoption. It remains unclear whether the rumour, the patents or competition with RSA were decisive, although all three factors likely played a role.

A shift in the approach

Turning to the present and the standardisation of PQC, NIST appears to have taken a forward-looking approach to intellectual property rights. A notable feature of the PQC rollout is NIST’s facilitation of patent licences for the key encapsulation mechanism Kyber, part of FIPS 203. In response to concerns about patents claiming aspects of lattice-based key encapsulation, NIST negotiated two royalty-free licences covering United States and French patent portfolios. The US portfolio, with PCT application number WO2013152725A1, concerns a key-exchange mechanism using pairing with errors, building on the principle of learning with errors, the cryptographic primitive used in Kyber. The French portfolio, stemming from patent FR2956541B1, relates to a method for secure communication that may be used for key exchange or messaging in resource-constrained environments.

The licensors agreed to suspend enforcement rights on a royalty-free basis for implementations of Kyber in accordance with NIST’s specification ​[5]​. Notably, only excerpts of the licence have been released, so details such as any licence fees remain unknown. This proactive approach is important because standards depend on certainty. Implementers require clear intellectual property terms in addition to clear technical specifications. By addressing these issues, NIST reduces legal friction and facilitates widespread adoption of secure communication methods for governments and individuals alike.

Conclusion

These examples demonstrate that intellectual property rights play a vital role in cryptography and are often contentious. Some argue that patents should be avoided entirely, but the reality is that patents can incentivise research and do not necessarily impede adoption if managed appropriately. Compared to the telecommunications industry, where standard-essential patenting and licensing is routine, cryptography has historically handled such matters on an ad hoc basis. However, greater awareness and foresight are emerging. Perhaps the future of cryptography will also embrace FRAND licensing on a broad scale?

​​References

​​

​[1]  ​E. Roberts, “RSA Public Key Encryption,” Stanford University, 5 June 2000. [Online]. Available: https://cs.stanford.edu/people/eroberts/cs201/projects/software-patents/rsa.html. [Accessed 19 December 2025].

​[2]  ​RSA, “RSA Security Releases RSA Encryption Algorithm into Public Domain,” 6 September 2000. [Online]. Available: https://web.archive.org/web/20071120112201/http://www.rsa.com/press_release.aspx?id=261. [Accessed 19 December 2025].

​[3]  ​D. J. Bernstein, “Irrelevant patents on elliptic-curve cryptography,” [Online]. Available: https://cr.yp.to/ecdh/patents.html. [Accessed 7 January 2026].

​[4]  ​RSA Laboratories, “Are elliptic curve cryptosystems patented?,” [Online]. Available: https://web.archive.org/web/20130524001754/http://www.rsa.com/rsalabs/node.asp?id=2325. [Accessed 7 January 2026].

​[5]  ​National Institute of Standards and Technology, “NIST PQC License Summary and Excerpts,” [Online]. Available: https://csrc.nist.gov/csrc/media/Projects/post-quantum-cryptography/documents/selected-algos-2022/nist-pqc-license-summary-and-excerpts.pdf. [Accessed 7 January 2026]. ​

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.